Rockwell Medical (NASDAQ:RMTI) Rating Increased to Strong-Buy at RODMAN&RENSHAW

Rockwell Medical (NASDAQ:RMTI) was upgraded by RODMAN&RENSHAW to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Rodman & Renshaw assumed coverage on Rockwell Medical in a research report on Thursday. They set a “buy” rating and a $5.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Rockwell Medical in a research report on Wednesday, September 11th. Finally, StockNews.com raised shares of Rockwell Medical from a “hold” rating to a “buy” rating in a report on Wednesday.

Rockwell Medical Price Performance

Shares of RMTI opened at $2.36 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.60. The stock has a fifty day moving average price of $3.70 and a 200 day moving average price of $2.60. The company has a market cap of $76.11 million, a P/E ratio of -47.20 and a beta of 1.50. Rockwell Medical has a 12 month low of $1.16 and a 12 month high of $5.15.

Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Tuesday, November 12th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. Rockwell Medical had a negative net margin of 1.25% and a positive return on equity of 8.55%. The business had revenue of $28.32 million for the quarter, compared to the consensus estimate of $25.99 million. On average, research analysts forecast that Rockwell Medical will post -0.03 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd boosted its position in Rockwell Medical by 45.7% during the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock valued at $113,000 after buying an additional 8,922 shares during the period. Concurrent Investment Advisors LLC bought a new stake in Rockwell Medical in the 3rd quarter worth approximately $40,000. Verus Capital Partners LLC bought a new position in Rockwell Medical in the third quarter worth approximately $51,000. State Street Corp increased its holdings in Rockwell Medical by 21.5% in the 3rd quarter. State Street Corp now owns 95,004 shares of the company’s stock worth $377,000 after acquiring an additional 16,800 shares in the last quarter. Finally, Barclays PLC purchased a new stake in Rockwell Medical during the 3rd quarter valued at approximately $90,000. 23.31% of the stock is owned by institutional investors and hedge funds.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.